Summary

Adjuvant androgen deprivation therapy (ADT), including a luteinizing hormone-releasing hormone analogue (LHRHA) for 2 to 3 years, is the standard of care before, during, and after radiotherapy for patients with localized prostate cancer at high risk of recurrence. However, the optimal regimen remains unclear. This article discusses the phase 3 trial of Enzalutamide in Androgen Deprivation Therapy with Radiation Therapy for High Risk, Clinically Localized, Prostate Cancer [ENZARAD; Australian New Zealand Clinical Trials Registry ACTRN12614000126617]